MarketCap
Facebook
X
Telegram
Bellerophon Therapeutics EBITDA | BLPH
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Bellerophon Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.4 M | -20.2 M | -26.3 M | -17.5 M | -27.9 M | -24.6 M | -23.8 M | -46.6 M | -59.8 M | -61.6 M | -46.1 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -17.5 M | -61.6 M | -34.2 M |
Quarterly EBITDA Bellerophon Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.17 M | -5.26 M | 1.48 M | - | -5.12 M | -6.54 M | -5.64 M | - | -4.8 M | -5.23 M | -5.86 M | -8.15 M | -8.26 M | -5.76 M | -4.11 M | -4.32 M | -4.59 M | -4.22 M | -4.34 M | -4.68 M | -6.83 M | -7.87 M | -8.49 M | -7.31 M | -6.18 M | -11.1 M | -4.78 M | -7.29 M | -4.22 M | -5.16 M | -7.09 M | -10.9 M | -11.2 M | -11.6 M | -12.9 M | -12.8 M | -15.5 M | -17 M | -14.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.48 M | -17 M | -7.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.31 | 6.5 % | $ 166 M |  Schweiz |
 |
ADMA Biologics
ADMA
|
199 M | $ 9.7 | 3.21 % | $ 2.31 B |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-41.1 M | $ 27.89 | 0.3 % | $ 4.23 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 13.3 | 1.06 % | $ 364 M |  Israel |
 |
AbbVie
ABBV
|
15.8 B | $ 265.08 | 0.02 % | $ 469 B | USA |
 |
Axsome Therapeutics
AXSM
|
-166 M | $ 193.45 | 0.24 % | $ 9.62 B | USA |
 |
Aytu BioScience
AYTU
|
-4.38 M | $ 2.28 | 2.24 % | $ 28.1 M | USA |
 |
Adagene
ADAG
|
-21 M | $ 2.97 | 0.62 % | $ 175 M |  China |
 |
Abeona Therapeutics
ABEO
|
-86.9 M | $ 5.53 | 2.65 % | $ 293 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
-7.8 M | $ 4.04 | 0.24 % | $ 2.7 M | USA |
 |
Evelo Biosciences
EVLO
|
-106 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
489 M | $ 62.21 | 0.06 % | $ 11.9 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-37.8 M | $ 4.85 | 0.2 % | $ 929 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 2.16 | 0.45 % | $ 3.56 M | Israel |
 |
Achieve Life Sciences
ACHV
|
228 K | $ 7.83 | 0.87 % | $ 341 M | USA |
 |
Catalyst Biosciences
CBIO
|
14 M | $ 14.19 | 1.17 % | $ 1.27 B | USA |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M |  Britain |
 |
C4 Therapeutics
CCCC
|
-113 M | $ 3.08 | 0.3 % | $ 255 M | USA |
 |
Codexis
CDXS
|
-36.5 M | $ 1.38 | 0.72 % | $ 120 M | USA |
 |
Allakos
ALLK
|
-115 M | - | - | $ 28.6 M | USA |
 |
Cerus Corporation
CERS
|
-7.26 M | $ 2.6 | 4.3 % | $ 496 M | USA |
 |
Coherus BioSciences
CHRS
|
-180 M | $ 1.26 | 1.48 % | $ 148 M | USA |
 |
Celldex Therapeutics
CLDX
|
-284 M | $ 31.12 | 0.28 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-10.6 M | $ 4.04 | 4.94 % | $ 49.3 M | Israel |
 |
AbCellera Biologics
ABCL
|
-199 M | $ 12.31 | 0.12 % | $ 3.68 B | Canada |
 |
Aclaris Therapeutics
ACRS
|
-75.9 M | $ 5.26 | 2.69 % | $ 645 M | USA |
 |
Фармсинтез
LIFE
|
-22.6 M | - | - | - |  Russia |
 |
Clovis Oncology
CLVS
|
-44.2 M | - | -7.23 % | $ 13 M | USA |
 |
Cocrystal Pharma
COCP
|
-8.95 M | $ 1.19 | 1.26 % | $ 13.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
64.9 M | $ 22.45 | 1.05 % | $ 711 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
45.9 M | $ 112.94 | 3.29 % | $ 11.7 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-513 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-85.1 M | $ 7.74 | 0.19 % | $ 103 M | USA |
 |
Cardiff Oncology
CRDF
|
-48.6 M | $ 1.31 | 0.74 % | $ 87.6 M | USA |
 |
Curis
CRIS
|
-5.54 M | $ 0.95 | 0.98 % | $ 12.5 M | USA |
 |
CorMedix
CRMD
|
151 M | $ 7.69 | 0.06 % | $ 554 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-645 M | $ 55.76 | 1.2 % | $ 5.01 B | Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
-42.9 M | $ 12.54 | 8.21 % | $ 990 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-76 M | - | - | $ 401 M | USA |
 |
Cue Biopharma
CUE
|
-25.6 M | $ 31.71 | 2.62 % | $ 3 B | USA |
 |
CEL-SCI Corporation
CVM
|
-22.8 M | $ 1.68 | 0.59 % | $ 13.5 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-602 M | $ 65.81 | 0.04 % | $ 7.9 M | USA |
 |
Axon Enterprise
AXON
|
21.1 M | $ 450.61 | 1.61 % | $ 35.2 B | USA |
 |
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
-34.4 M | $ 7.56 | 7.16 % | $ 355 M | USA |
 |
Denali Therapeutics
DNLI
|
-544 M | $ 20.46 | 5.52 % | $ 3.53 B | USA |
 |
Precision BioSciences
DTIL
|
-50.7 M | $ 6.36 | 10.62 % | $ 81.6 M | USA |
 |
Dyadic International
DYAI
|
-7.19 M | $ 0.41 | 3.72 % | $ 14.8 M | USA |
 |
Editas Medicine
EDIT
|
-155 M | $ 2.69 | 0.17 % | $ 239 M | USA |
 |
Edesa Biotech
EDSA
|
-7.79 M | $ 3.97 | 1.46 % | $ 22.5 M | USA |